Tracers / [225Ac]Ac-PSMA-617
[225Ac]Ac-PSMA-617
Also written as PSMA-617; [Ac-225]Ac-PSMA-617; Ac-225-PSMA-617; Pluvicto
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- investigational
- Syntheses indexed
- 21
What it is
- Compound class
- PSMA-617 – urea-based PSMA-targeting small molecule (DOTA-conjugated peptidomimetic)
- Target / mechanism
- Targets prostate-specific membrane antigen (PSMA) PMID 34385780
- Clinical application
- Targeted alpha therapy for metastatic castration-resistant prostate cancer PMID 32802197
- Theranostic pair
- <a href="/tracers/in111-psma617/">in111-psma617</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | about 45% | approximately 95% | PSMA-617 Novartis | 42159963 2026 EJNMMI Radiopharm Chem For 225Ac labeling of PSMA-617, 225AcCl3 (0.92 MBq) was added to 0.2 M NH4OAc buffer (pH 5.2, 100 µL) in a 0.5 mL Eppendorf tube (LoBind), followed by the addition of PSMA-617 (1.0 nmol, 1.0 µL). — about 45% for [212Pb]Pb-PSMA-617 and [225Ac]Ac-PSMA-617 |
| — | — | — | — | — | — | 41783574 2026 Drug Des Devel Ther |
| — | — | — | — | — | — | 38855174 2024 Theranostics |
| — | — | — | — | — | — | 38773983 2024 Theranostics |
| — | — | — | — | — | PSMA-617 | 38577331 2024 Front Oncol |
| Manual synthesis | — | — | — | — | PSMA-617 precursor ABX | 37797974 2023 J Nucl Med Radiolabeling was performed as previously described |
| — | — | — | — | — | PSMA-617 | 35177427 2022 J Nucl Med |
| Manual synthesis | — | SPE | 85%–87% | 97%–99% | PSMA-617 ABX | 34385780 2021 Indian J Nucl Med Ac-225 PSMA was prepared by adding the required amount (50–150 μg) of the peptidic precursor (PSMA-617) in 1 ml ascorbate buffer. — the radiopeptide was obtained with an adequate yield of 85%–87% |
| — | — | — | — | — | PSMA-617 | 33778927 2021 Curr Oncol Rep |
| Manual synthesis | — | — | — | — | PSMA-617 CMR, Center of Molecular Research, Moscow, Russia | 32802197 2020 Theranostics A stock solution of 225AcCl3 in 0.01 M HCl was added to the sodium ascorbate buffer-PSMA-617 mixture and heated at 90 °C for 10 min. |
| — | — | — | — | — | — | 31240331 2019 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | PSMA-617 ABX | 31107537 2019 Mutagenesis |
| — | — | — | — | — | PSMA-617 ABX | 30232539 2019 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 42437859 2026 Discov Oncol |
| — | — | — | — | — | PSMA-617 | 40358362 2025 J Med Chem |
| — | — | — | — | — | — | 38218192 2024 Lancet Oncol |
| — | — | — | — | — | PSMA-617 | 34477385 2021 J Med Chem |
| — | — | — | >99% | 98 ± 1% | PSMA-617 | 34250876 2022 Curr Radiopharm PSMA-617 precursor was dissolved in 25 μL metal-free water (0.67 mg/mL) and combined with 500 μL 0.05M Tris buffer, pH 9. — high radiochemical yield (57 ± 3 μCi, >99%) |
| — | — | SPE | — | — | PSMA-617 | 34053430 2022 Curr Radiopharm PSMA-617, DOTATATE were radiolabelled with 225Actinium in 0.1 M HCl in the presence of ascorbate buffer solution and passed through the C-18 light cartridge for purification |
| — | — | — | — | — | — | 31601699 2020 J Nucl Med |
| — | — | — | — | — | — | 31101746 2020 J Nucl Med |
Need this precursor?We can point you to suppliers for [225Ac]Ac-PSMA-617, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 35 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68, In-111. Compound class inferred from precursor name (not stated outright) -- PMID 42159963: 'PSMA-617 (1.0 nmol, 1.0 µL)'. Stage set/updated at stage 23 from PMID 38773983: 'At the forefront of clinical trials with 225Ac in PCa are PSMA-targeted TAT agents, notably [225Ac]Ac-PSMA-617, [225Ac]Ac-PSMA-I&T and [225Ac]Ac-J591.'.